Vitamin D and calcium supplements have varied effects on breast cancer risk

June 05, 2006

A large multicenter randomized clinical trial reported that supplementation with calcium and vitamin D did not reduce breast cancer risk in the overall population. However, exploratory analyses suggest the effect of vitamin D and calcium supplements on breast cancer risk may vary according to a woman's initial supplement use.

"Our findings suggest that calcium and vitamin D supplementation may reduce breast cancer risk in some women, but more research is needed to clarify these results," said Rowan T. Chlebowski, MD, PhD, Medical Oncologist at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and the study's lead author. "We can't yet make a general recommendation about how much calcium and vitamin D individuals should take each day as supplements."

This study, part of the Women's Health Initiative, included 36,282 postmenopausal women without prior breast cancer at 40 centers in the United States. Breast cancer incidence was compared between 18,176 women randomly assigned to receive 1000 mg of elemental calcium carbonate and 400 IU of vitamin D3 daily, and 18,106 who received a placebo.

After a median follow-up time of seven years, breast cancer incidence did not differ significantly between the two groups overall (2.9% with breast cancer in the calcium/vitamin D group versus 3.0% in the placebo group). Among the women who did develop breast cancer, mean breast tumor size was smaller in the calcium/vitamin D group (1.54 cm versus 1.71 cm, p=0.05).

Women were allowed to continue personal use of calcium and vitamin D supplements as well as those provided in the randomized trial. Among the 19,115 women not reporting any supplement use at entry, the risk of developing breast cancer was reduced by 18% in the calcium / vitamin D group compared with women who received a placebo (Hazard Ratio (HR) 0.82, 95% Confidence Interval (CI) 0.70-0.97). In contrast, no reduction was seen in women already using any calcium and vitamin D supplements at entry (HR 1.14, 95% CI 0.96-1.36). The interaction p value was 0.008, suggesting a different effect in these two subgroups.

Dr. Chlebowski explained that "planned analyses of vitamin D metabolites in the blood may help interrupt the findings."

Previous observational studies have suggested that vitamin D and calcium may protect against breast cancer. Because natural sources of vitamin D are limited (mostly sun exposure and oily fish), vitamin D is added to some foods, such as milk. The Institute of Medicine has concluded that data are insufficient to set an official recommended daily allowance (RDA) for vitamin D, but advises most adults to get at least 400 IU per day (600 IU for those 70 year years or older). Currently, about a third of U.S. women regularly use supplements containing calcium and vitamin D.
-end-
The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) is one of the largest independent, not-for-profit biomedical research institutes in Los Angeles County. Affiliated with both the David Geffen School of Medicine at UCLA and the Harbor-UCLA Medical Center, the Institute has an annual budget of over $72 million and currently supports more than 1,000 research studies in areas such as cardiology, emerging infections, cancer, dermatology, women's health, reproductive health, vaccine research, respiratory physiology, neonatology, molecular biology, and genetics.

LA BioMed

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.